| ctDNA-Guided Neoadjuvant Therapy in HER2+ Breast Cancer | Docetaxel anhydrous | Phase 2 | Not yet recruiting | Jin Sun Bitar | Nov 20, 2026 |
| Camrelizumab Plus Nab-Paclitaxel and Cisplatin Before Surgery for Locally Advanced Head and Neck Cancer: a Randomized Phase III Trial | Paclitaxel | Phase 3 | Not yet recruiting | Xuekui Liu | Nov 19, 2026 |
| ASTAR: Sacituzumab Govitecan For Breast Cancer | Docetaxel anhydrous | Phase 2 | Not yet recruiting | Massachusetts General Hospital | Nov 19, 2026 |
| Delayed Application of Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer | Paclitaxel | Phase 3 | Not yet recruiting | Goethe University | Nov 17, 2026 |
| Iparomlimab and Tuvonralimab Injection (QL1706)Combined With Chemotherapy (AG) and SBRT as First-Line Treatment for Locally Advanced Pancreatic Cancer | Paclitaxel | Phase 2 | Active, not recruiting | Tongji Hospital | Nov 16, 2026 |
| A Phase II Study of Nab-Paclitaxel Combined With Retlirafusp Alfa and Apatinib in Patients With Advanced Mucosal Melanoma | Paclitaxel | Phase 2 | Recruiting | Sun Yat-sen University | Nov 13, 2026 |
| Clinical Study of Ivonescimab Combined With Concurrent Chemoradiotherapy in the Treatment of Advanced Non-small Cell Lung Cancer | Paclitaxel | Phase 2 | Not yet recruiting | Guizhou Medical University | Nov 13, 2026 |
| AIM2-NLRP3 Inflammasome Dual Inhibitor on hsCRP | Colchicine | Not applicable | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Nov 12, 2026 |
| MIRV in Combination With Suvemcitug for Partially Platinum-Sensitive Ovarian Cancer | Mirvetuximab soravtansine | Phase 2 | Not yet recruiting | Tongji Hospital | Nov 12, 2026 |
| PDS Versus NACT-IDS in AI-Selected Advanced Epithelial Ovarian Cancer | Paclitaxel, Docetaxel anhydrous | Phase 2 | Not yet recruiting | Shanghai Gynecologic Oncology Group | Nov 12, 2026 |
| RELEASE Ph2 RT-310 BPH Study | Paclitaxel | Phase 2 | Not yet recruiting | Resurge Therapeutics Inc. | Nov 10, 2026 |
| A Multicenter, Prospective Single-arm Study of Multimodal Thermal Therapy Combined With Toripalimab and AG Chemotherapy in the Treatment of Advanced Pancreatic Cancer | Paclitaxel | Not applicable | Not yet recruiting | Ruijin Hospital | Nov 10, 2026 |
| Predicting Benefit From Anthracycline-Free Adjuvant Chemotherapy in High-Risk HER2-Negative Breast Cancer | Docetaxel anhydrous | — | Active, not recruiting | Peking Union Medical College Hospital | Nov 9, 2026 |
| Tislelizumab Combined With Tofacitinib and Docetaxel for NSCLC After Failure of First-Line Immunotherapy | Docetaxel anhydrous | Phase 2 | Recruiting | Anhui Provincial Hospital | Nov 9, 2026 |
| QLS4131 Plus Isa-V-CHOP in Newly Diagnosed, HIV-Negative PBL: A Single-Center, Single-Arm, Phase II Study | Vincristine | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | Nov 6, 2026 |
| Venetoclax Plus Inotuzumab Reduced-Intensity Induction Sequentially Followed by Blinatumomab in B-ALL | Vincristine | Not applicable | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | Nov 6, 2026 |
| Hs-CRP-Guided Colchicine Treatment Targets in Very-High-Risk Patients With Coronary Artery Disease After PCI (TARGET-CHD) | Colchicine | Not applicable | Not yet recruiting | Sir Run Run Shaw Hospital | Nov 5, 2026 |
| A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010) | Polatuzumab vedotin | Phase 2 / Phase 3 | Not yet recruiting | Merck Sharp & Dohme LLC | Nov 5, 2026 |
| Smart 3: A Multi-Center Phase 2 Trial Of Golcadomide, Glofitamab And Polatuzumab Vedotin (G2P) For Patients With Newly Diagnosed Large B-Cell Lymphoma | Polatuzumab vedotin | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | Nov 5, 2026 |
| A Trial to Evaluate the Efficacy of Pirtobrutinib and Epcoritamab Compared With R-(Mini)-CHOP for Treatment of Patients With DLBCL-type Richter Transformation | Vincristine | Phase 2 | Recruiting | German CLL Study Group | Nov 5, 2026 |
| Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | Vincristine | Phase 1 | Not yet recruiting | City of Hope Medical Center | Nov 3, 2026 |
| Risk-Enabled Therapy After Initiating EV/Pembro for Bladder Cancer | Enfortumab vedotin | Phase 2 | Recruiting | Fox Chase Cancer Center | Nov 2, 2026 |
| Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan Trial | Polatuzumab vedotin | Phase 2 | Not yet recruiting | University of Washington | Nov 2, 2026 |
| A Study to Evaluate Surovatamig Combined With R-CHOP in Participants of 18 to < 80 Years of Age With Previously Untreated Large B-cell Lymphoma With IPI Score 2 to 5 | Polatuzumab vedotin, Vincristine | Phase 3 | Not yet recruiting | AstraZeneca | Nov 2, 2026 |
| Efficacy and Safety of Polatuzumab Vedotin, Rituximab Combined With Reduced-dose Cyclophosphamide, Doxorubicin and Prednisone Regimen in the Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma: A Multicenter, Single-arm, Prospective Study | Polatuzumab vedotin | Phase 4 | Recruiting | The First Hospital of Jilin University | Nov 2, 2026 |
| MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A) | Docetaxel anhydrous | Phase 1 / Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | Nov 2, 2026 |
| Colchicine in Pulmonary Artery Hypertension Patients | Colchicine | Phase 2 | Not yet recruiting | Ain Shams University | Oct 30, 2026 |
| Low-Dose Apatinib Plus Chemotherapy in ADC-Pretreated HER2-Positive and HER2-Low Advanced Breast Cancer | Vinorelbine | Phase 2 | Not yet recruiting | Yunnan Cancer Hospital | Oct 30, 2026 |
| Deutenzalutamide and Hormone Therapy Before and After Surgery With Docetaxel Before Surgery for High-Risk Localized or Locally Advanced Prostate Cancer | Docetaxel anhydrous | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Oct 30, 2026 |
| Serplulimab, DOS and Lenvatinib Combine With PIPAC in the Oligometastatic Peritoneal Metastasis of Gastric/Gastroesophageal Junction Adenocarcinoma | Docetaxel anhydrous | Phase 2 | Not yet recruiting | Fujian Cancer Hospital | Oct 29, 2026 |
| Real-World Study of Mirvetuximab Soravtansine in Adult Participants With Platinum-Resistant FRα-Positive Ovarian, Fallopian Tube, and Peritoneal Cancer | Mirvetuximab soravtansine | — | Recruiting | AbbVie | Oct 27, 2026 |
| Implantable Microdevices for in Situ Evaluation of Drug Responses in Lung Cancer | Vinorelbine | Early phase 1 | Recruiting | Oliver Jonas | Oct 23, 2026 |
| A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)] | Enfortumab vedotin | Phase 1 / Phase 2 | Recruiting | Daiichi Sankyo | Oct 22, 2026 |
| Preliminary Clinical Study of Entinostat in Children With Malignant Soft Tissue Sarcoma Harboring PAX-family Gene Abnormalities | Vincristine | Phase 1 | Recruiting | Beijing Tongren Hospital | Oct 22, 2026 |
| Randomized Interventional Clinical Trial on the Prevention of Atrial Fibrillation Using Colchicine, Amiodarone And a Posterior Pericardiotomy. | Colchicine | Phase 3 | Not yet recruiting | Elsan | Oct 21, 2026 |
| Bispecific Antibody-Based Holding/Bridging Therapy Before CAR-T in Aggressive B-Cell Lymphomas | Polatuzumab vedotin | Phase 2 | Recruiting | National Research Center for Hematology, Russia | Oct 20, 2026 |
| Goflikicept for Resolution and Prevention of Attacks in Pediatric and Adolescent Patients With Colchicine-Resistant or Colchicine-Intolerant Familial Mediterranean Fever | Colchicine | Phase 3 | Not yet recruiting | R-Pharm | Oct 19, 2026 |
| A Study of SYS6043 Versus Investigator's Choice Chemotherapy as First-Line Treatment in Patients With Unresectable Locally Recurrent or Metastatic Triple-Negative Breast Cancer | Eribulin | Phase 3 | Not yet recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | Oct 19, 2026 |
| Antibody-Drug Conjugate Plus Immunotherapy Versus Immunotherapy Plus Chemotherapy for Extensive Transurethrally Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer | Disitamab vedotin | Phase 2 | Not yet recruiting | Tianjin Medical University Second Hospital | Oct 16, 2026 |
| Peripheral Neuropathy in Patients Receiving Enfortumab Vedotin and Pembrolizumab as Perioperative Systemic Therapy for Urothelial Carcinoma | Enfortumab vedotin | — | Recruiting | Comprehensive Cancer Center Munich (CCCM) | Oct 13, 2026 |
| Enfortumab Vedotin for the Treatment of Unresectable or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer, Anaplastic Thyroid Cancer, Medullary Thyroid Cancer, or NUT Carcinoma | Enfortumab vedotin | Phase 2 | Not yet recruiting | Northwestern University | Oct 7, 2026 |
| A Ph2, Colchicine For Inflammatory Carotid Injury And Disease Evolution After Radiotherapy | Colchicine | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | Oct 5, 2026 |
| Perioperative Systemic Therapies in Muscle-Invasive Bladder Cancer (GUARDIANS) | Enfortumab vedotin | — | Recruiting | LMU Klinikum | Oct 2, 2026 |
| Clinical and Therapeutic Outcomes by Molecular Subtype in Breast Cancer | Trastuzumab emtansine | — | Recruiting | Fundación Santa Fe de Bogota | Oct 2, 2026 |
| Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer | Cabazitaxel | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | Oct 1, 2026 |
| DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder Cancer | Disitamab vedotin | Phase 1 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Oct 1, 2026 |
| The Primary Objective of the Trial is to Evaluate the Effect of the Addition of Belantamab Mafodotin to Standard of Care Therapy on the Titres of Serum Anti-dsDNA Antibodies in Patients With Previously Treated SLE. | Belantamab mafodotin | Phase 2 | Not yet recruiting | Medical Association for the Study of Cancer Biology and Treatment | Sep 28, 2026 |
| Colchicine for Primary Prevention of Cardiovascular Disease in Adults With Type 2 Diabetes | Colchicine | Phase 2 | Recruiting | Tan Tock Seng Hospital | Sep 24, 2026 |
| Study of Belantamab Mafodotin, Cevostamab, Pomalidomide for RRMM Patients (MAPLE) | Belantamab mafodotin | Phase 1 | Not yet recruiting | Canadian Myeloma Research Group | Sep 21, 2026 |
| Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer | Enfortumab vedotin, Mirvetuximab soravtansine, Trastuzumab emtansine | Phase 2 | Not yet recruiting | Fudan University | Sep 17, 2026 |
| A Phase II Study of HLX22 in Combination With Trastuzumab and Chemotherapy in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients | Eribulin, Vinorelbine | Phase 2 | Not yet recruiting | Shanghai Henlius Biotech | Sep 17, 2026 |
| A Phase 3 Trial in Advanced Epithelioid Mesothelioma | Vinorelbine | Phase 3 | Not yet recruiting | Vivace Therapeutics, Inc | Sep 17, 2026 |
| A Phase 2 Study Evaluating Bladder Preservation With Enfortumab Vedotin Plus Pembrolizumab in Patients With Muscle-Invasive Urothelial Cancer | Enfortumab vedotin | Phase 2 | Not yet recruiting | University of Utah | Sep 16, 2026 |
| A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell Lymphoma | Vincristine | Phase 1 / Phase 2 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | Sep 14, 2026 |
| A Study of Ivonescimab in Combination With Enfortumab Vedotin vs Pembrolizumab in Combination With Enfortumab Vedotin in Metastatic Urothelial Carcinoma | Enfortumab vedotin | Phase 2 / Phase 3 | Recruiting | Summit Therapeutics | Sep 11, 2026 |
| Colchicine Effect on Amyotrophic Lateral Sclerosis Patients | Colchicine | Phase 2 | Not yet recruiting | Azienda Ospedaliero-Universitaria di Modena | Sep 10, 2026 |
| A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers | Eribulin | Phase 1 / Phase 2 | Not yet recruiting | Advenchen Pharmaceuticals, LLC. | Sep 10, 2026 |
| Pirtobrutinib Plus Methotrexate-Based Chemoimmunotherapy for Systemic DLBCL With CNS Involvement | Polatuzumab vedotin, Vincristine | Phase 2 | Not yet recruiting | Pengpeng Xu | Sep 10, 2026 |
| A Study to Evaluate the Efficacy and Safety of Intravesical Instillation of Disitamab Vedotin Combined With Toripalimab in Patients With HER2-Positive High-Risk Non-Muscle Invasive Bladder Cancer Who Are BCG-Naïve or Have BCG Failure | Disitamab vedotin | Phase 1 | Not yet recruiting | Xiangya Hospital of Central South University | Aug 25, 2026 |
| Orelabrutinib Combined With Pola-R-CHP as First-Line Treatment for Patients With Intermediate- to High-Risk DLBCL | Polatuzumab vedotin | Not applicable | Recruiting | The First Affiliated Hospital of Xiamen University | Aug 21, 2026 |
| Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer | Disitamab vedotin | Phase 2 / Phase 3 | Not yet recruiting | Tianjin Medical University Second Hospital | Aug 10, 2026 |
| Comparing Lower Versus Standard Doses of Belantamab Mafodotin With Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma. | Belantamab mafodotin | Phase 2 | Not yet recruiting | Polish Myeloma Consortium | Aug 6, 2026 |
| Mirvetuximab Soravtansine Combined With Suvemcitug in Platinum-Resistant Recurrent Ovarian Cancer | Mirvetuximab soravtansine | Phase 2 | Not yet recruiting | Peking University Third Hospital | Aug 3, 2026 |
| A Single-Arm Study of Sintilimab and Disitamab Vedotin for Locally Advanced Eyelid Sebaceous Gland Carcinoma | Disitamab vedotin | Phase 2 | Not yet recruiting | West China Hospital | Aug 3, 2026 |
| TAlquetamab and BeLantamab Mafodotin in Relapsed/Refractory Multiple Myeloma (TaBleMM) | Belantamab mafodotin | Phase 1 | Not yet recruiting | Montefiore Medical Center | Jul 22, 2026 |
| Neoadjuvant Disitamab Vedotin, Toripalimab, and Radiotherapy for High-risk UTUC ( LUXUS07.1 ) | Disitamab vedotin | Phase 2 | Not yet recruiting | Peking University First Hospital | Jul 22, 2026 |
| Efficacy and Safety of Brentuximab Vedotin Combined With Lisaftoclax in CD30+ Cutaneous T-cell Lymphoma (CTCL) | Brentuximab vedotin | Phase 2 | Not yet recruiting | Peking University First Hospital | Jul 21, 2026 |
| Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer | Disitamab vedotin | Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Jul 21, 2026 |
| Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBC | Disitamab vedotin | Phase 3 | Recruiting | Zhiquan Hu | Jul 9, 2026 |
| A Real-world Study of Mirvetuximab Soravtansine (MIRV) in Ovarian Cancer Patients of Expression of Folate Receptor α(FRα) | Mirvetuximab soravtansine | — | Not yet recruiting | NING LI-GYN | Jul 8, 2026 |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Mirvetuximab Soravtansine-gynx in Adults With Folate Receptor-Alpha Positive, Platinum-Resistant Ovarian Cancer in a Real-World Setting | Mirvetuximab soravtansine | — | Not yet recruiting | AbbVie | Jul 7, 2026 |
| Tisotumab Vedotin in Squamous Cell Carcinoma of the Vulva | Tisotumab vedotin | Phase 2 | Not yet recruiting | GOG Foundation | Jun 29, 2026 |
| A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer | Trastuzumab emtansine | Phase 3 | Recruiting | GeneQuantum Healthcare (Suzhou) Co., Ltd. | Jun 29, 2026 |
| Optimal Application Timing of ADC Drugs for Advanced Breast Cancer | Eribulin, Vinorelbine | Phase 2 | Recruiting | Liaoning Cancer Hospital & Institute | Jun 18, 2026 |
| Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple Myeloma | Belantamab mafodotin | — | Not yet recruiting | PETHEMA Foundation | Jun 9, 2026 |
| Real-life Experience of Brentuximab Vedotin Plus CHP as First-line Treatment of CD30+ Peripheral T-cell Lymphomas in Spain | Brentuximab vedotin | — | Recruiting | Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Jun 3, 2026 |
| A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma | Belantamab mafodotin | Phase 1 / Phase 2 | Not yet recruiting | Centre Hospitalier Universitaire de Saint Etienne | May 29, 2026 |
| Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma | Belantamab mafodotin | Phase 2 | Not yet recruiting | GlaxoSmithKline | May 29, 2026 |
| AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01) | Cabazitaxel | Phase 3 | Recruiting | AstraZeneca | May 28, 2026 |
| Study on the Mechanism of ADC Drug Evaluation Based on Immune Co-culture of Lung Cancer Organoids | Trastuzumab emtansine | — | Recruiting | Guangzhou Institute of Respiratory Disease | May 28, 2026 |
| A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment | Belantamab mafodotin | Phase 1 | Not yet recruiting | GlaxoSmithKline | May 27, 2026 |
| Neoadjuvant Trastuzumab, Pertuzumab Plus Metronomic Vinorelbine for Elderly HER2-Positive Breast Cancer | Vinorelbine | Not applicable | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | May 15, 2026 |
| GIM27-THERapy: a Study to Describe the Effectiveness of Tucatinib in Combination With Capecitabine and Trastuzumab in the Treatment of Metastatic HER-2 Positive Breast Cancer Patients in Real World Setting | Trastuzumab emtansine | — | Recruiting | Fondazione Oncotech | May 13, 2026 |
| Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis | Trastuzumab emtansine | Phase 3 | Recruiting | SWOG Cancer Research Network | May 11, 2026 |
| Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma | Brentuximab vedotin | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | May 7, 2026 |
| Extracellular Vesicles and Chemotherapy-Induced Peripheral Neuropathy | Eribulin | Not applicable | Recruiting | Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | Apr 30, 2026 |
| A Study of 9MW2821 Versus Chemotherapy in Participants With Previously Treated Locally Advanced or Metastatic Triple-Negative Breast Cancer | Eribulin, Vinorelbine | Phase 3 | Not yet recruiting | Mabwell (Shanghai) Bioscience Co., Ltd. | Apr 29, 2026 |
| Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL | Vinblastine | Phase 2 | Recruiting | M.D. Anderson Cancer Center | Apr 27, 2026 |
| Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast Cancer | Eribulin, Vinorelbine | — | Recruiting | Fudan University | Apr 24, 2026 |
| A Real-World Study on the Impact of Different Adjuvant Treatment Regimens on Prognosis in Non-pCR Patients With HER2-Positive Breast Cancer After Neoadjuvant Therapy | Trastuzumab emtansine | — | Not yet recruiting | Hebei Medical University Fourth Hospital | Apr 20, 2026 |
| A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care | Eribulin | Phase 3 | Recruiting | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Apr 16, 2026 |
| BV-CHP Real-life and Biological Evidences in Patients With sALCL | Brentuximab vedotin | — | Not yet recruiting | Fondazione Italiana Linfomi - ETS | Mar 12, 2026 |
| Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis | Vinblastine | Not applicable | Recruiting | West China Second University Hospital | Feb 24, 2026 |
| De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer | Trastuzumab emtansine | Phase 2 | Active, not recruiting | National Medical Research Radiological Centre of the Ministry of Health of Russia | Feb 19, 2026 |
| A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) | Vinflunine | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | Feb 19, 2026 |
| Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4) | Plinabulin | Phase 3 | Not yet recruiting | BeyondSpring Pharmaceuticals Inc. | Jan 23, 2026 |
| Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer | Telisotuzumab vedotin | Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | Jan 7, 2026 |
| Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment | Brentuximab vedotin | Phase 2 | Recruiting | City of Hope Medical Center | Dec 10, 2025 |
| BrEto-TCL - Defining the Role of Brentuximab and Etoposide for Optimizing First-line Therapy of T-cell Lymphomas | Brentuximab vedotin | Phase 3 | Enrolling by invitation | N.N. Petrov National Medical Research Center of Oncology | Dec 2, 2025 |
| Comparison of AVD + Low-Dose Nivolumab vs. PET-Adapted BEACOPP-like in Advanced cHL | Vinblastine | Phase 2 | Recruiting | St. Petersburg State Pavlov Medical University | Nov 18, 2025 |
| AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer | Mirvetuximab soravtansine | Phase 3 | Recruiting | AstraZeneca | Oct 20, 2025 |
| A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer | Cabazitaxel | Phase 3 | Recruiting | Amgen | Oct 9, 2025 |
| A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer | Mirvetuximab soravtansine | Phase 3 | Recruiting | Eli Lilly and Company | Oct 9, 2025 |
| PET-Adapted First-Line Therapy With Nivolumab for Advanced Hodgkin Lymphoma | Vinblastine | Phase 2 | Recruiting | National Research Center for Hematology, Russia | Oct 6, 2025 |
| Effect of Neoadjuvant Chemotherapy on MRI Accuracy Before Cystectomy | Vinblastine | Not applicable | Recruiting | Assiut University | Oct 2, 2025 |
| Brentuximab Vedotin in CutAneous T-cell Lymphomas (CTCL): Post-allogeneic Hematopoietic Stem Cell Transplant Maintenance | Brentuximab vedotin | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | Sep 17, 2025 |
| GSL Synthetase Inhibitor Eliglustat Combined With CD30 Target Immunotherapy for the Treatment of of CD30+ Lymphoma | Brentuximab vedotin | Phase 1 / Phase 2 | Recruiting | Chinese PLA General Hospital | Aug 24, 2025 |
| Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma | Paclitaxel docosahexaenoic acid | Phase 2 | Recruiting | Affiliated Hospital of Guangdong Medical University | Aug 22, 2025 |
| Chemoimmunotherapy for ALK+ Relapsed/Refractory ALCL | Vinblastine | Phase 2 | Recruiting | New York Medical College | Jun 10, 2025 |
| Nivo40-AVD for Advanced Classic Hodgkin Lymphoma | Vinblastine | Phase 2 | Recruiting | National Medical Research Radiological Centre of the Ministry of Health of Russia | May 22, 2025 |
| Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2) | Vinblastine | Phase 2 | Recruiting | AstraZeneca | May 7, 2025 |
| Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer | Tisotumab vedotin | Phase 4 | Recruiting | Pfizer | May 1, 2025 |
| A Study to Investigate Efficacy and Safety of Different Dose Regimen of Oral Cabazitaxel Tablet in Adult Participants with Prostate Cancer | Cabazitaxel | Phase 2 | Not yet recruiting | Jina Pharmaceuticals Inc. | Mar 24, 2025 |
| Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC | Cabazitaxel | Phase 3 | Recruiting | Novartis Pharmaceuticals | Mar 3, 2025 |
| Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer | Cabazitaxel | Phase 2 | Recruiting | Case Comprehensive Cancer Center | Dec 17, 2024 |
| Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute) | Cabazitaxel | Phase 3 | Active, not recruiting | Amgen | Nov 18, 2024 |
| Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial | Cabazitaxel | Phase 2 | Recruiting | Alliance for Clinical Trials in Oncology | Oct 9, 2024 |
| A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Telisotuzumab vedotin | Phase 2 | Recruiting | AbbVie | Aug 23, 2024 |
| A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) | Tisotumab vedotin | Phase 3 | Active, not recruiting | Merck Sharp & Dohme LLC | Jun 14, 2024 |
| ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer | Anvatabart opadotin | Phase 2 | Recruiting | Laura Huppert, MD, BA | Jan 25, 2024 |
| First Line Pembrolizumab, Plinabulin Plus Etoposide and Platinum (EP) for ES-SCLC | Plinabulin | Phase 2 | Recruiting | Xiaorong Dong | Feb 27, 2023 |
| Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004) | Plinabulin | Phase 2 | Active, not recruiting | Peking Union Medical College Hospital | Oct 31, 2022 |
| Study of Plinabulin and Pegfilgrastim in People With Multiple Myeloma Undergoing an Autologous Hematopoietic Stem Cell Transplant (AHCT) | Plinabulin | Phase 2 | Active, not recruiting | Memorial Sloan Kettering Cancer Center | Nov 23, 2021 |
| A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Telisotuzumab vedotin | Phase 3 | Recruiting | AbbVie | Jun 16, 2021 |
| Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer | Anetumab ravtansine | Phase 1 | Active, not recruiting | National Cancer Institute (NCI) | Jan 25, 2019 |
| Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | Anetumab ravtansine | Phase 2 | Active, not recruiting | National Cancer Institute (NCI) | Jul 16, 2018 |
| Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | Telisotuzumab vedotin | Phase 2 | Active, not recruiting | AbbVie | May 29, 2018 |
| Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors | Tisotumab vedotin | Phase 2 | Active, not recruiting | Seagen, a wholly owned subsidiary of Pfizer | Apr 2, 2018 |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | Ladiratuzumab vedotin | Phase 1 / Phase 2 | Recruiting | Hoffmann-La Roche | Feb 6, 2018 |
| A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations | Vinflunine | Phase 3 | Active, not recruiting | Janssen Research & Development, LLC | Jan 4, 2018 |
| Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma | Anetumab ravtansine | Phase 1 / Phase 2 | Active, not recruiting | National Cancer Institute (NCI) | Apr 24, 2017 |
| A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors | Telisotuzumab vedotin | Phase 1 | Active, not recruiting | AbbVie | Mar 28, 2014 |
| Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery | Ixabepilone, Patupilone | Phase 1 | Active, not recruiting | National Cancer Institute (NCI) | Jun 17, 2011 |
| Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer | Ixabepilone, Patupilone | Phase 2 | Active, not recruiting | National Cancer Institute (NCI) | Sep 15, 2009 |
| Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy | Ixabepilone, Patupilone | Phase 2 | Active, not recruiting | M.D. Anderson Cancer Center | Apr 7, 2009 |